Stay updated with breaking news from Dan Bloomfield. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Abelacimab, a Dual-Acting Factor XI / XIa Inhibitor, Demonstrated an Unprecedented Reduction in Bleeding in the Largest and Longest Head-toHead Study Comparing a Factor XI Inhibitor to a DOAC
Anthos Therapeutics halts their phase 2 AZALEA-TIMI 71 trial due to significant reduction in bleeding events with abelacimab, making it a potential breakthrough in anticoagulation therapy for atrial fibrillation.
Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated ...
Anthos Therapeutics has announced that Abelacimab has received FDA Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
This is the second Fast Track designation Anthos has received for abelacimab in less than two months. The therapeutic is also the first Factor XI inhibitor to start enrolling patients in Phase 3 trials.